









Markets
/
Stocks
/
nasdaq-psnl
/

Personalis Inc

PSNL

6.240USD

-1.080-14.75%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

177.82MMarket Cap

LossP/E TTM



Personalis Inc

6.240

-1.080-14.75%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Personalis Inc

Currency: USD Updated: 2026-03-27

Key Insights

Personalis Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 118 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.43.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Personalis Inc's Score

Industry at a Glance

Industry Ranking

118 / 391

Overall Ranking

234 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Personalis Inc Highlights

StrengthsRisks

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

Growing

The company is in a growing phase, with the latest annual income totaling USD 69.65M.

Undervalued

The company’s latest PE is -6.96, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 60.12M shares, increasing 11.19% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 13.10K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.429

Target Price

+56.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Personalis Inc is 6.48, ranking 241 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 17.34M, representing a year-over-year increase of 3.24%, while its net profit experienced a year-over-year increase of 44.97%.

Score

Industry at a Glance

Previous score

6.48

Change



Financials

8.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.91

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Personalis Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Personalis Inc is 6.10, ranking 327 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.96, which is -94.40% below the recent high of -0.39 and -92.93% above the recent low of -13.43.

Score

Industry at a Glance

Previous score

6.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 118/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Personalis Inc is 8.29, ranking 140 out of 391 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.429

Target Price

+80.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Personalis Inc

PSNL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Personalis Inc is 6.73, ranking 151 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.41 and the support level at 5.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.18

Change

-0.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.124

Sell

RSI(14)

33.882

Neutral

STOCH(KDJ)(9,3,3)

19.058

Sell

ATR(14)

0.572

High Vlolatility

CCI(14)

-152.578

Sell

Williams %R

92.308

Oversold

TRIX(12,20)

-0.793

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

7.076

Sell

MA10

7.152

Sell

MA20

7.502

Sell

MA50

8.430

Sell

MA100

8.579

Sell

MA200

7.540

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Personalis Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 67.70%, representing a quarter-over-quarter increase of 27.29%. The largest institutional shareholder is Catherine Wood, holding a total of 7.88M shares, representing 7.53% of shares outstanding, with 7.47% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Merck & Co Inc

14.04M

Tempus AI Inc

12.72M

T. Rowe Price Investment Management, Inc.

2.88M

+128.05%

Lightspeed Venture Partners

8.16M

ARK Investment Management LLC

Star Investors

7.91M

+11.29%

BlackRock Institutional Trust Company, N.A.

4.33M

+14.07%

The Vanguard Group, Inc.

Star Investors

3.01M

-4.16%

abrdn Inc.

2.39M

+35.72%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Personalis Inc is 3.14, ranking 165 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Personalis Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.